Prolonged survival in patients with beta-thalassemia major treated with deferoxamine

The Journal of Pediatrics

Volumn 118, Issue 4 PART 1, 1991, Pages 540-545

  Ehlers, Kathryn H ^a,b   Giardina, Patricia J ^a,b   Lesser, Martin L ^a,b   Engle, Mary Allen ^a,b   Hilgartner, Margaret W ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DRUG EFFECT; HEART DISEASE; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; BODY BURDEN; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DEFEROXAMINE; HUMAN; IRON; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THALASSEMIA;

EID: 0025878026     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(05)83374-8     Document Type: Article

References (26)

1. Late cardiac complications of chronic severe refractory anemia with hemochromatosis
2. Longitudinal study of cardiac function in thalassemia major
3. The cardiac manifestations of thalassemia major: natural history, noninvasive cardiac diagnostic studies and results of cardiac catheterization
4. Bone marrow transplantation in patients with thalassemia
5. Current strategies in the management of Cooley's anemia
6. Chelation therapy in beta thalassemia major. III. The role of splenectomy in achieving iron balance
7. New approaches to transfusion management of thalassemia
8. Continuous subcutaneous administration of desferrioxamine in patients with iron overload
9. Long-term chelation therapy in thalassaemia major effect on liver iron concentration liver histology and clinical progress
10. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
11. A prospective evaluation of iron chelation therapy in children with severe β-thalassemia: a six-year study
12. Iron state and hepatic disease in patients with thalassaemia major, treated with long-term subcutaneous desferrioxamine
13. Early left ventricular dysfunction and chelation therapy in thalassemia major
14. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major
15. Deferoxamine improves left ventricular function in β-thalassemia
16. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy
17. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
18. Survival and desferrioxamine in thalassaemia major
19. Survival and causes of death in thalassaemia major
20. Studies on congenital hemolytic syndromes. IV. Gastrointestinal absorbtion of iron
21. Chelation therapy in beta thalassemia major. I. Intravenous and subcutaneous desferrioxamine
22. Ferrioxamine excretion in iron loaded man
23. Desferrioxamine (DFO) use protects against heart disease and death from transfusional iron-overload in thalassemia major [Abstract]